As of June 18, 2025, Burzynski Research Institute Inc (BZYR) reports a ROE (Return on Equity) of 3329.03%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Burzynski Research Institute Inc's ROE (Return on Equity)
Over recent years, Burzynski Research Institute Inc's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2025-02-28 | 3329.03% |
| 2024-02-29 | 5316.20% |
| 2023-02-28 | 6673.63% |
| 2022-02-28 | -80715.70% |
| 2021-02-28 | 2626.53% |
This slight downward trend highlights how Burzynski Research Institute Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Burzynski Research Institute Inc's ROE (Return on Equity) to Peers
To better understand Burzynski Research Institute Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Burzynski Research Institute Inc (BZYR) | 3329.03% |
| TetraLogic Pharmaceuticals Corp (TLOG) | 837.00% |
| Anthera Pharmaceuticals Inc (ANTH) | 489.06% |
| Nanobac Pharmaceuticals Inc (NNBP) | 278.37% |
| Protalex Inc (PRTX) | 239.83% |
| VG Life Sciences Inc (VGLS) | 119.71% |
Compared to its competitors, Burzynski Research Institute Inc's ROE (Return on Equity) is higher than all peers, suggesting efficient use of shareholder equity to generate profits.